TEVA
Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome
Article Summary
BUY- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA and TASE: TASE) submitted a New Drug Application for ecopipam, a first-in-class investigational therapy for pediatric Tourette syndrome, supported by positive Phase 3 data published in JAMA Neurology showing significantly delayed time to relapse compared with placebo in pediatric patients who achieved clinical response during open-label treatment period.
- The drug received Orphan Drug and Fast Track designations from the FDA for the treatment of pediatric patients with Tourette Syndrome, with the most common adverse events including somnolence, insomnia, anxiety, headache, and insomnia.
- The NDA submission reflects momentum in Teva- Pharmaceutical Industries Ltd.
- ADR's innovative pipeline through its recent acquisition of the asset and advances its Pivot to Growth strategy.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 5.8% | 25% | 35.0 ptsBelow Screener (5.8%) - Weak growth |
| EPS Growth Next 5Y ? | 5.5% | 25% | 20.0 ptsWeak (5.5%) - Low expectations |
| Target Price Upside ? | 32.6% | 20% | 85.0 ptsLarge Upside (32.6%) - Target: $41.75 vs Current: $31.48 |
| Gross Margin % ? | 52.2% | 15% | 80.0 ptsVery Healthy (52.2%) - High-quality margins |
| Drawdown from 52-Wk High ? | -15.7% | 15% | 40.0 ptsMild Pullback (-15.7%) - Light entry opportunity |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About TEVA
- Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally.
- It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
- The company also focuses on the central nervous system (CNS), respiratory, and oncology areas.
- It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies.
- The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO to treat neurodegenerative and movement disorders – chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder.
- The company offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names.
- It has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH.
- The company was founded in 1901 and is based in Tel Aviv-Yafo, Israel.